192 related articles for article (PubMed ID: 25275413)
1. The use of (68)Ga DOTATATE PET/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma.
Novruzov F; Aliyev JA; Jaunmuktane Z; Bomanji JB; Kayani I
Clin Nucl Med; 2015 Jan; 40(1):47-9. PubMed ID: 25275413
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
3. Improvement in diagnosis of metastatic pituitary carcinoma by 68Ga DOTATATE PET/CT.
Xiao J; Zhu Z; Zhong D; Ma W; Wang R
Clin Nucl Med; 2015 Feb; 40(2):e129-31. PubMed ID: 24873798
[TBL] [Abstract][Full Text] [Related]
4. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
Acar E; Çapa Kaya G; Durak H
Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172
[TBL] [Abstract][Full Text] [Related]
5. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome.
Novruzov F; Mehmetbeyli L; Aliyev JA; Abbasov B; Mehdi E
Clin Nucl Med; 2019 Jun; 44(6):e415-e417. PubMed ID: 30789400
[TBL] [Abstract][Full Text] [Related]
7. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma.
Gains JE; Bomanji JB; Fersht NL; Sullivan T; D'Souza D; Sullivan KP; Aldridge M; Waddington W; Gaze MN
J Nucl Med; 2011 Jul; 52(7):1041-7. PubMed ID: 21680680
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-DOTATATE PET/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit.
Lybik N; Wale DJ; Wong KK; Liao E; Viglianti BL
Clin Nucl Med; 2021 Jun; 46(6):505-506. PubMed ID: 33782291
[TBL] [Abstract][Full Text] [Related]
10. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
Teunissen JJ; Kwekkeboom DJ; Kooij PP; Bakker WH; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():107S-14S. PubMed ID: 15653659
[TBL] [Abstract][Full Text] [Related]
11. 68Ga DOTATATE PET/CT of Synchronous Meningioma and Prolactinoma.
Basu S; Ranade R; Hazarika S
Clin Nucl Med; 2016 Mar; 41(3):230-1. PubMed ID: 26462040
[TBL] [Abstract][Full Text] [Related]
12. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
14. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
16. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
[TBL] [Abstract][Full Text] [Related]
17. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
[TBL] [Abstract][Full Text] [Related]
18. PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study.
Wang H; Hou B; Lu L; Feng M; Zang J; Yao S; Feng F; Wang R; Li F; Zhu Z
J Nucl Med; 2018 Mar; 59(3):523-528. PubMed ID: 28775202
[TBL] [Abstract][Full Text] [Related]
19. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report.
Waligórska-Stachura J; Gut P; Sawicka-Gutaj N; Liebert W; Gryczyńska M; Baszko-Błaszyk D; Blanco-Gangoo AR; Ruchała M
J Neurosurg; 2016 Aug; 125(2):346-9. PubMed ID: 26636388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
